Table 2 JAK2 p.V617F mutation in nine NSCLCs. Co-occurrence with well-characterized NSCLC oncogenic mutations in KRAS, EGFR, and BRAF are shown
Sample ID | Tumor type | Tumor cell (%) | Sequencing depth (x) | JAK2 p.V617F allele fraction (%) | Co-occurring mutation (allele fraction %) |
|---|---|---|---|---|---|
592 | Non-small cell carcinoma | 30 | 1999 | 8.2 | KRAS p.G12V (17.2) |
664 | Adenocarcinoma with squamous features | 50 | 1996 | 7 | BRAF p.V600E (27.3) |
717 | Adenocarcinoma | 40 | 1273 | 2 | - |
915 | Favoring adenocarcinoma | 60 | 1539 | 2.1 | EGFR exon19 del (52.1) |
1182 | Adenocarcinoma | 40 | 1997 | 2.4 | BRAF p.V600E (10.4) |
1200 | Mucinous adenocarcinoma | 10 | 1422 | 10.5 | KRAS p.G12V (4.8) |
1527 | Adenocarcinoma | 30 | 1997 | 10.8 | - |
1588 | Adenocarcinoma, acinar type | 20 | 892 | 6.5 | - |
1825 | Adenocarcinoma with mucinous features | 30 | 1998 | 13.4 | KRAS p.G12C (25.4) |